Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.45 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.79 |
| ▸ | HMGCR | P04035 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | SLC13A5 | Q86YT5 | 3/20 | 0.42 |
| ▸ | ACLY | P53396 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL2064212 | 1.00 | ALDH1A1 (0.79) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL1231330 | 0.92 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL27580631 | 0.90 | ALDH1A1 (0.71) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL2396390 | 0.89 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL30359537 | 0.89 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL11584082 | 0.89 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL3417188 | 0.89 | ALDH1A1 (1.00) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL240402 | 0.89 | ALDH1A1 (1.00) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL842 | 0.89 | ALDH1A1 (1.00) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL1331942 | 0.89 | ALDH1A1 (1.00) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12171884-B2 | Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-24 | — | — | US | claimed |
| CN-117776936-A | Preparation method of choline dihydrogen citrate | 济南亚西亚药业有限公司 | 2024-03-29 | — | — | CN | claimed |
| EP-4218739-A2 | MESOPOROUS SILICA NANOPARTICLES WITH LIPID BILAYER COATING FOR CARGO DELIVERY | The Regents of The University of California (US) | 2023-08-02 | — | — | EP | claimed |
| WO-2022115488-A1 | IMMUNOGENIC NANOVESICLES FOR CANCER IMMUNOTHERAPY | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2022-06-02 | — | — | WO | claimed |
| US-20220160644-A1 | MESOPOROUS SILICA NANOPARTICLES WITH LIPID BILAYER COATING FOR CARGO DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-26 | — | — | US | claimed |
| US-20200383929-A1 | MESOPOROUS SILICA NANOPARTICLES WITH LIPID BILAYER COATING FOR CARGO DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-12-10 | — | — | US | claimed |
| EP-3735250-A1 | SCALE UP SYNTHESIS OF SILICASOME NANOCARRIERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-11-11 | — | — | EP | claimed |
| US-10765636-B2 | Mesoporous silica nanoparticles with a lipid bilayer coating for cargo delivery | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-08 | — | — | US | claimed |
| US-20190160015-A1 | MESOPOROUS SILICA NANOPARTICLES WITH A LIPID BILAYER COATING FOR CARGO DELIVERY | UNIV CALIFORNIA (US) | 2019-05-30 | — | — | US | claimed |
| US-20160141725-A1 | Electrolytes and Metal Hydride Batteries | BASF CORPORATION | 2016-05-19 | — | — | US | claimed |
| US-12629387-B2 | Composition of antiviral agent for use in prophylactic or post-exposure treatment of infectious or respiratory diseases | INSPIRMED CORP. (TW) | 2026-05-19 | — | — | US | disclosed |
| US-20260069538-A1 | CXCR4 ANTAGONIST LOADED LIPOSOMES AND SILICASOMES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-03-12 | — | — | US | disclosed |
| US-12539338-B2 | Nano-enabled immunotherapy in cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-02-03 | — | — | US | disclosed |
| US-20250281417-A1 | MESOPOROUS SILICA NANOPARTICLES WITH LIPID BILAYER COATING FOR CARGO DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-09-11 | — | — | US | disclosed |
| US-12383499-B2 | Scale up synthesis of silicasome nanocarriers | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-08-12 | — | — | US | disclosed |
| CN-1250791-A | Pigment prepns. | MERCK PATENT GMBH (DE) | 2000-04-19 | — | — | CN | disclosed |
| CN-1244212-A | Improved expression vectors | PROCTER & GAMBLE (US) | 2000-02-09 | — | — | CN | disclosed |
| CN-1039430-C | Detergent additives | PROCTER & GAMBLE (US) | 1998-08-05 | — | — | CN | disclosed |
| CN-1085942-A | Detergent additives | PROCTER & GAMBLE (US) | 1994-04-27 | — | — | CN | disclosed |
| US-4013577-A | POLYETHER SULFATE, NON-PHOSPHATE BUILDERS | COLGATE-PALMOLIVE COMPANY (US) | 1977-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12629387-B2 | Composition of antiviral agent for use in prophylactic or post-exposure treatment of infectious or respiratory diseases | IFNAR1, NPC1, SGMS1 | MEN1 3475/4885ESR1 3977/4885ESR2 1284/4885 |
| US-12539338-B2 | Nano-enabled immunotherapy in cancer | IDO1, IDO2, BID | MEN1 1618/4885ESR1 4363/4885ESR2 4287/4885 |
| US-20260069538-A1 | CXCR4 ANTAGONIST LOADED LIPOSOMES AND SILICASOMES | CXCL12, CXCR4, CXCR5 | MEN1 1635/4885ESR1 549/4885ESR2 1279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.